LEF-1 is a prosurvival factor in chronic lymphocytic leukemia and is expressed in the preleukemic state of monoclonal B-cell lymphocytosis.

The canonical Wnt signaling pathway is pathogenic in a variety of cancers. We previously identified aberrant expression of the Wnt pathway transcription factor and target gene lymphoid enhancer binding factor-1 (LEF1) in chronic lymphocytic leukemia (CLL). This suggested that the Wnt signaling pathway has a role in the biology of CLL. In this study, we performed a Wnt pathway analysis using gene expression profiling and identified aberrant regulation of Wnt pathway target genes, ligands, and signaling members in CLL cells. Furthermore, we identified aberrant protein expression of LEF-1 specifically in CLL but not in normal mature B-cell subsets or after B-cell activation. Using the T cell-specific transcription factor/LEF (TCF/LEF) dual luciferase reporter assay, we demonstrated constitutive Wnt pathway activation in CLL, although the pathway was inactive in normal peripheral B cells. Importantly, LEF-1 knockdown decreased CLL B-cell survival. We also identified LEF-1 expression in CD19(+)/CD5(+) cells obtained from patients with monoclonal B-cell lymphocytosis, suggesting a role for LEF-1 early in CLL leukemogenesis. This study has identified the constitutive activation and prosurvival function of LEF-1 and the Wnt pathway in CLL and uncovered a possible role for these factors in the preleukemic state of monoclonal B-cell lymphocytosis.

[1]  B. Boman,et al.  Evidence that APC regulates survivin expression: a possible mechanism contributing to the stem cell origin of colon cancer. , 2001, Cancer research.

[2]  T. Shanafelt,et al.  Monoclonal B-cell lymphocytosis (MBL): biology, natural history and clinical management , 2010, Leukemia.

[3]  Yuhai Tu,et al.  Identification of a global gene expression signature of B-chronic lymphocytic leukemia. , 2003, Molecular cancer research : MCR.

[4]  D. Chung,et al.  Regulation of vascular endothelial growth factor by the Wnt and K-ras pathways in colonic neoplasia. , 2001, Cancer research.

[5]  T. Kadesch,et al.  The Notch Intracellular Domain Can Function as a Coactivator for LEF-1 , 2001, Molecular and Cellular Biology.

[6]  Hong Gao,et al.  VentX, a novel lymphoid-enhancing factor/T-cell factor-associated transcription repressor, is a putative tumor suppressor. , 2010, Cancer research.

[7]  A. Capobianco,et al.  Mastermind-like 1 Is a specific coactivator of beta-catenin transcription activation and is essential for colon carcinoma cell survival. , 2007, Cancer research.

[8]  Y. Tu,et al.  Gene Expression Profiling of B Cell Chronic Lymphocytic Leukemia Reveals a Homogeneous Phenotype Related to Memory B Cells , 2001, The Journal of experimental medicine.

[9]  R. Grosschedl,et al.  LEF1-mediated regulation of Delta-like1 links Wnt and Notch signaling in somitogenesis. , 2004, Genes & development.

[10]  Terry M. Therneau,et al.  Faster cyclic loess: normalizing RNA arrays via linear models , 2004, Bioinform..

[11]  D. Mukhopadhyay,et al.  Aberrant regulation of pVHL levels by microRNA promotes the HIF/VEGF axis in CLL B cells. , 2009, Blood.

[12]  Neil E Caporaso,et al.  B-cell clones as early markers for chronic lymphocytic leukemia. , 2009, The New England journal of medicine.

[13]  Michael J. Green,et al.  Monoclonal B lymphocytes with the characteristics of "indolent" chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts. , 2002, Blood.

[14]  R Grosschedl,et al.  ALY, a context-dependent coactivator of LEF-1 and AML-1, is required for TCRalpha enhancer function. , 1997, Genes & development.

[15]  S. Richards,et al.  Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. , 2008, The New England journal of medicine.

[16]  Kathleen R. Cho,et al.  ITF-2, a downstream target of the Wnt/TCF pathway, is activated in human cancers with beta-catenin defects and promotes neoplastic transformation. , 2002, Cancer cell.

[17]  T. Kipps,et al.  Activation of the Wnt signaling pathway in chronic lymphocytic leukemia. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[18]  M. Waterman,et al.  The human LEF-1 gene contains a promoter preferentially active in lymphocytes and encodes multiple isoforms derived from alternative splicing. , 2000, Nucleic acids research.

[19]  Deborah A. Bowen,et al.  Brief report: natural history of individuals with clinically recognized monoclonal B-cell lymphocytosis compared with patients with Rai 0 chronic lymphocytic leukemia. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  D. Jelinek,et al.  Divergent Effects of BAFF on Human Memory B Cell Differentiation into Ig-Secreting Cells1 , 2007, The Journal of Immunology.

[21]  F. McCormick,et al.  Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. , 1999, Nature.

[22]  Y. Yashiro‐Ohtani,et al.  Notch1 co-opts lymphoid enhancer factor 1 for survival of murine T-cell lymphomas. , 2007, Blood.

[23]  A. Sparks,et al.  Identification of c-MYC as a target of the APC pathway. , 1998, Science.

[24]  I. Screpanti,et al.  Constitutively activated Notch signaling is involved in survival and apoptosis resistance of B-CLL cells. , 2009, Blood.

[25]  Marc K Hellerstein,et al.  In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. , 2005, The Journal of clinical investigation.

[26]  Christian Buske,et al.  A novel role for Lef-1, a central transcription mediator of Wnt signaling, in leukemogenesis , 2008, The Journal of experimental medicine.

[27]  T. Kipps,et al.  Ethacrynic Acid Exhibits Selective Toxicity to Chronic Lymphocytic Leukemia Cells by Inhibition of the Wnt/β-Catenin Pathway , 2009, PloS one.

[28]  Karine Hovanes,et al.  β-catenin–sensitive isoforms of lymphoid enhancer factor-1 are selectively expressed in colon cancer , 2001, Nature Genetics.

[29]  Lisa L. Smith,et al.  Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. , 2006, Blood.

[30]  A. Schambach,et al.  LEF-1 is crucial for neutrophil granulocytopoiesis and its expression is severely reduced in congenital neutropenia , 2006, Nature Medicine.

[31]  R Grosschedl,et al.  Wnt signaling regulates B lymphocyte proliferation through a LEF-1 dependent mechanism. , 2000, Immunity.

[32]  J. Bladé,et al.  Pathogenesis and progression of monoclonal gammopathy of undetermined significance , 2008, Leukemia.